Clinical trials
Stage IV Fallopian Tube Cancer clinical trials
Below are recruiting stage iv fallopian tube cancer clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05574673Recruiting
Study of DNA repair traits in ovarian cancer patients
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
København Ø, Region SjællandAges 18–100 - NCT05538091RecruitingPhase 2
Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05460000RecruitingPhase 2
Niraparib after early ovarian cancer chemo—short vs long
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
InnsbruckAges 18 years+ - NCT05429970Recruiting
Reducing stress before ovarian cancer surgery with two medicines
This study tests whether giving two commonly used medicines before surgery—one that can lower stress on the body (a beta-blocker) and one that reduces inflammation (a COX-2 inhibitor)—can improve outcomes compared with standard care. It’s for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who are having open surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT05128825RecruitingPhase 2
Azenosertib for platinum-resistant ovarian cancer with cyclin e1
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT04811703RecruitingPhase 1
Testing aerosol chemotherapy through the belly for advanced ovarian cancer
This Phase 1 study tests a new way to deliver chemotherapy inside the abdomen (belly) using a pressurized aerosol during a procedure, along with standard blood (IV) chemotherapy. It may help people with advanced ovarian cancer whose tumors have not progressed but are not removable with surgery yet.
LilleAges 18–75 - NCT04701645RecruitingPhase 1
Microdevice study for advanced ovarian or related cancers
This Phase 1 study tests a tiny implanted device placed in the abdomen to help evaluate or treat advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you’d also have additional tests and surgery as part of your usual care plan.
Boston, MassachusettsAges 18 years+ - NCT04606914RecruitingPhase 2
Carboplatin plus mirvetuximab for advanced ovarian cancer after chemo
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Birmingham, AlabamaAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Miami, FloridaAges 18 years+ - NCT03968406RecruitingPhase 1
Talazoparib plus radiation for recurrent gynecologic cancers
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Baltimore, MarylandAges 18 years+ - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Phoenix, ArizonaAges 18 years+ - NCT06466382Recruiting
Personalized cancer therapy for advanced ovarian cancer
This trial tests whether a treatment plan tailored to your specific tumor and health can work better for advanced ovarian, peritoneal, or fallopian tube cancer. It aims to find the best therapy for each patient to improve outcomes.
Baden, Canton of AargauAges 18 years+ - NCT06638593Recruiting
Comparing open vs. robotic surgery for pelvic masses up to 8cm
This study compares two types of minimally invasive surgery—traditional laparoscopic (keyhole) versus robotic-assisted—for removing complex ovarian cysts or masses up to 8cm that haven't spread. The goal is to see which approach might offer better recovery and outcomes for women with these growths.
GuildfordAges 18–100 - NCT04111978RecruitingPhase 3
Maintenance hormone therapy after ovarian cancer responds
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
GrazAges 18 years+ - NCT03025477RecruitingPhase 2
Testing two first-treatment options for advanced ovarian cancer
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
DijonAges 18–75 - NCT06141265RecruitingPhase 2
Niraparib maintenance after chemo and Avastin for advanced ovarian cancer
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
Beijing, Beijing MunicipalityAges 18–75 - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT05952453RecruitingPhase 2
New ovarian cancer treatment with chemo plus maintenance medicines
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Birmingham, AlabamaAges 18 years+
Hear when a new Stage IV Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stage iv fallopian tube cancer?
- Yes. Clin2 currently lists 44 recruiting stage iv fallopian tube cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stage iv fallopian tube cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stage iv fallopian tube cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.